Read + Share
Yu M. iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1
receptor agonist-An effective type 2 diabetes treatment option in China. Diabetes Obes Metab 2025 Oct 20. doi: 10.1111/dom.70192.
PMID: 41116700
|
 |
|
Yu M. iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1
receptor agonist-An effective type 2 diabetes treatment option in China. Diabetes Obes Metab 2025 Oct 20. doi: 10.1111/dom.70192.
PMID: 41116700
|
|
|
|